Zobrazeno 1 - 10
of 34
pro vyhledávání: '"M. Fesneau"'
Autor:
Luc Bauchet, Denys Fontaine, D. Larrieu‐Ciron, M. Andraud, H. Aubriot‐Lorton, Fabien Forest, G. Runavot, Shai Rosenberg, I. Carpiuc, François Labrousse, Christine Desenclos, Annie Laquerrière, Georges Noël, Olivier Chinot, Catherine Godfraind, Patrick Beauchesne, Jean-Yves Delattre, Caroline Dehais, T. Cruel, Danchristian Chiforeanu, F. Dhermain, Dominique Cazals-Hatem, Claude Gaultier, W. Lahiani, Marie-Laure Tanguy, C. Dehais, S. Elouadhani‐Hamdi, Pomone Richard, François Ghiringhelli, Olivier Langlois, Ca. Maurage, Dominique Figarella-Branger, Ahmed Idbaih, Carole Ramirez, Philippe Menei, François Ducray, Benoit Lhermitte, Nabila Elarouci, M. Campone, F. Vandenbos‐Burel, Mj. Motso‐Fotso, C. Blechet, Nicolas Desse, Sandrine Eimer, Valérie Rigau, Agusti Alentorn, Anne Jouvet, Damien Ricard, Mc. Tortel, T. Khallil, Clovis Adam, Hugues Loiseau, L. Bekaert, Henri Sevestre, Chiara Villa, M. Fesneau, Isabelle Quintin-Roue, Antoine Petit, Philippe Colin, Elodie Vauleon, S. Lopez, S. Gaillard, Guillaume Gauchotte, Antoine F. Carpentier, Phong Dam-Hieu, Md. Diebold, Yannick Marie, Thierry Faillot, Serge Milin, Aurélien de Reyniès, Emmanuelle Lechapt-Zalcman, Fabrice Parker, E. Cohen‐Moyal, Delphine Loussouarn, Emmanuelle Uro-Coste, Em. Gueye, Audrey Rousseau, F. Ducray, M‐I Mihai, Aurelie Kamoun, Karima Mokhtari
Publikováno v:
Oncologist
Oncologist, AlphaMed Press, 2018, ⟨10.1634/theoncologist.2017-0495⟩
Oncologist, 2018, ⟨10.1634/theoncologist.2017-0495⟩
Oncologist, AlphaMed Press, 2018, ⟨10.1634/theoncologist.2017-0495⟩
Oncologist, 2018, ⟨10.1634/theoncologist.2017-0495⟩
Background 1p/19q-codeleted anaplastic gliomas have variable clinical behavior. We have recently shown that the common 9p21.3 allelic loss is an independent prognostic factor in this tumor type. The aim of this study is to identify less frequent geno
Autor:
Nathalie Hernández, Andrés Torres, Pascale Rouault, Nicolas Caradot, J. Waschnewski, M. Fesneau, Hauke Sonnenberg, Mathias Riechel, E. Eckert, N. Lengemann
Publikováno v:
Journal of Hydroinformatics. 20:1131-1147
Deterioration models can be successfully deployed only if decision-makers trust the modelling outcomes and are aware of model uncertainties. Our study aims to address this issue by developing a set of clearly understandable metrics to assess the perf
Autor:
Pascal Garaud, Yoann Pointreau, Caroline Lafond, M. Fesneau, O. Dupuis, Etienne Bardet, S. Chapet, G. Janoray, Gilles Calais, A. Robert
Publikováno v:
Cancer/Radiothérapie. 21:286-290
Purpose The main objective of this study was to evaluate the 5-year efficacy of exclusive laryngeal radiotherapy without node prophylactic irradiation for localized cancers of the vocal cords. Patients and methods We retrospectively reviewed charts f
Publikováno v:
Cancer/Radiothérapie. 21:222-225
Epithelioid hemangioendothelioma is a rare vascular tumour, with features between hemangiomas and angiosarcomas. Evolution remains mainly local but may also metastasize. Here, we report a case of a patient with a spinal epithelioid hemangioendothelio
Autor:
Celso Pouget, Sébastien Hergalant, Emilie Lardenois, Stéphanie Lacomme, Rémi Houlgatte, Catherine Carpentier, Caroline Dehais, Fabien Rech, Luc Taillandier, Marc Sanson, Romain Appay, Carole Colin, Dominique Figarella‐Branger, Shyue‐Fang Battaglia‐Hsu, Guillaume Gauchotte, Christine Desenclos, H. Sevestre, Philippe Menei, A. Rousseau, T. Cruel, S. Lopez, M.I. Mihai, A. Petit, R. Seizeur, I. Quintin‐Roué, C. Adam, F. Parker, S. Eimer, H. Loiseau, L. Bekaert, F. Chapon, D. Ricard, C. Godfraind, T. Khallil, D. Cazals‐Hatem, T. Faillot, C. Gaultier, M. C Tortel, I. Carpiuc, P. Richard, W. Lahiani, H. Aubriot‐Lorton, F. Ghiringhelli, C‐A Maurage, E. Le Rhun, E. M. Gueye, F. Labrousse, F. Ducray, D. Meyronet, O. Chinot, L. Bauchet, V. Rigau, P. Beauchesne, M. Campone, D. Loussouarn, D. Fontaine, F. Vandenbos‐Burel, A. Le. Floch, P. Roger, C. Blechet, M. Fesneau, A. Carpentier, A. Idbaih, J. Y. Delattre, K. Mokhtari, F. Bielle, S. Hamdi, M. Polivka, S. Milin, P. Colin, M. D. Diebold, D. Chiforeanu, E. Vauleon, O. Langlois, A. Laquerriere, F. Forest, M. J. Motso‐Fotso, M. Andraud, G. Runavot, B. Lhermitte, G. Noel, S. Gaillard, C. Villa, N. Desse, C. Rousselot‐Denis, I. Zemmoura, E. Cohen‐Moyal, E. Uro‐Coste, F. Dhermain
Publikováno v:
Brain Pathol
Brain Pathology
Brain Pathology, 2020, 30 (3), pp.465-478. ⟨10.1111/bpa.12788⟩
Brain Pathology, Wiley, 2020, 30 (3), pp.465-478. ⟨10.1111/bpa.12788⟩
Brain Pathology
Brain Pathology, 2020, 30 (3), pp.465-478. ⟨10.1111/bpa.12788⟩
Brain Pathology, Wiley, 2020, 30 (3), pp.465-478. ⟨10.1111/bpa.12788⟩
International audience; Anaplastic oligodendroglioma (AO), IDH‐mutant and 1p/19q codeleted (IDHmut+/1p19qcodel), is a high‐grade glioma with only limited prognostic markers. The primary objective of this study was to evaluate, by immunohistochemi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8810b3c3f3d699dfc454cfd29ae942ea
https://europepmc.org/articles/PMC8018020/
https://europepmc.org/articles/PMC8018020/
Autor:
R. Leloup, É. Champaux-Orange, H. Taste, S.K. Chomicki, O. Munier, T. Wachter, M. Fesneau, A. Valéry
Publikováno v:
Cancer/Radiothérapie. 22:737-738
Objectif de l’etude Le cancer du poumon non a petites cellules touche particulierement le sujet âge, toutefois les donnees sur cette population sont insuffisantes. Nous avons evalue les caracteristiques et la survie de ces patients en fonction de
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique. 21(3)
Epithelioid hemangioendothelioma is a rare vascular tumour, with features between hemangiomas and angiosarcomas. Evolution remains mainly local but may also metastasize. Here, we report a case of a patient with a spinal epithelioid hemangioendothelio
Publikováno v:
Cancer/Radiothérapie. 14:S120-S126
Resume Les cancers du canal anal representent 1,2% des cancers digestifs, et 6% des cancers ano-rectaux. Lorsqu’ils sont localises, le traitement de reference repose sur la radiotherapie associee ou non a la chimiotherapie par 5-fluoro-uracile et c
Publikováno v:
Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique. 14
Anal canal epidermoid carcinomas represent 1.2% of digestive cancers and 6% of ano-rectal cancers. For localized diseases, the treatment is based on radiotherapy with or without chemotherapy (5-FU and cisplatin or mitomycin), according to tumour and